Mabwell-b (2493.HK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 5 | 16 | 28 | 128 | 200 | 663 | 874 | 997 |
| Operating profit | CNY m | -955 | -860 | ||||||
| Net profit | CNY m | -607 | -757 | -955 | -1,053 | -1,044 | -969 | -940 | -605 |
| EPS reported | CNY | -2.43 | -2.36 | ||||||
| Operating cashflow per share | CNY | -0.73 | -1.92 | ||||||
| Capex per share | CNY | 0.40 | 0.34 | ||||||
| FCF per share | CNY | -1.12 | -2.25 | ||||||
| Free cash flow | CNY m | -448 | -898 | ||||||
| Net debt | CNY m | 959 | 1,061 | ||||||
| Book value equity | CNY m | 350 | 873 | ||||||
| Book value per share | CNY | 0.88 | 2.20 | ||||||
| Number of shares | m | 398.9 | 396.63 | ||||||
| DPS (TTM paid) | CNY | 0.20 | 0.11 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 27.25 | 10.90 | ||||||
| P/S LTM | x | 14.37 | 10.90 | ||||||
| P/FCF LTM | x | -21.26 | -10.61 | ||||||
| EV/EBITDA LTM | x | -16.36 | -15.24 | ||||||
| EV/Sales LTM | x | 15.99 | 12.56 | ||||||
| Earnings Yield LTM | % | -10.18% | -13.31% | ||||||
| FCF Yield | % | -4.70% | -9.43% | ||||||
| Quality | |||||||||
| ROE | % | -277.34% | -179.83% | ||||||
| ROIC | % | -27.74% | -18.44% | ||||||
| Operating margin | % | -1.44% | -98.36% | ||||||
| Gross margin | % | +90.27% | +74.55% | ||||||
| FCF/Sales | % | -67.61% | -102.72% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +231.62% | +337.49% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.82% | 0.00% | ||||||
| Dividend Growth | % | +18.88% | -32.13% | ||||||
| Payout Ratio | % | -8.09% | -6.84% | ||||||
| FCF/Debt | x | -0.17 | -0.27 | ||||||
| Net Debt/EBITDA | x | -1.66 | -1.62 | ||||||
| EBIT/Net interest | x | -10.52 | -7.72 | ||||||
| Net debt/market cap | % | +26.12% | +32.73% | ||||||
| Net debt/Equity | x | 2.74 | 1.21 | ||||||
| Gross debt/equity | x | 7.44 | 3.84 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provides oncology products, including 9MW2821, a Nectin-4 targeting drug candidate in the Phase III clinical trials for the treatment of cervical cancer; 7MW3711, a B7-H3 targeting ADC for the treatment of advanced malignant solid tumors; and 7MW4911, an ADC that targets CDH17. In addition, the company offers immunology products comprising 9MW1911, an anti-ST2 antibody that is in Phase I clinical trial for the treatment of COPD, and 9MW3811, an anti-IL-11 antibody that is in Phase I clinical trial. Its bone disorder product pipeline consists of 1MW5011, an oral tablet for the treatment of osteoarthritis. Additionally, it provides ophthalmology products include 9MW0813, a recombinant VEGF receptor-antibody fusion protein for the treatment of ocular diseases related to vascularization; 9MW0211, a recombinant anti-VEGF humanized monoclonal antibody injection that is in Phase III clinical trials for the treatment of neovascularization-related eye diseases, such as neovascular age-related macular degeneration. Further, the company's hematology product comprises 9MW3011, a recombinant humanized anti-TMPRSS6 monoclonal antibody that is in Phase I clinical trials for the treatment of polycythemia vera and iron overload disorders, including beta-thalassemia. The company was founded in 2017 and is headquartered in Shanghai, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free